Breaking the mold with #RNA—a# “ #RNAissance# ” of life science. . #RNAtherapeutics# #RNAdrugs# #Oligonucleotides# #mRNAtherapeutics# #mRNA# #siRNA# #RNAi# #Antisenseoligonucleotides# #Antisenseoligonucleotides# #ASO# #NucleicAcids# .

🧬 From nucleic acids to real-world impact. OTDC 2027 brings together emerging science in oligonucleotide therapeutics, RNA & mRNA medicines, and innovative delivery technologies. 📅 May 11–12, 2027 | 📍 Boston, MA & Virtual 🔗

🧬 Charting new horizons in nucleic acid medicine. OTDC 2027 explores emerging advances in oligonucleotide therapeutics, RNA & mRNA, innovative delivery technologies, and research collaboration—connecting ideas that can move the field forward. 📅 May 11–12, 2027 | 📍 Boston, MA

🧬 Better molecules. Smarter delivery. Real-world impact. OTDC 2027 brings together emerging advances in oligonucleotide therapeutics, RNA & mRNA, and innovative delivery technologies shaping the future of medicine. 📅 May 11–12, 2027 | 📍 Boston, MA & Virtual

Another big month in the books for Lightning: We hit 16x QoQ growth on the Lightning Cloud, kicked off a fleet-wide upgrade from H100s → H200s, and helped power Chronos, the data engine behind Therna Biosciences' AI RNA Biologist. And with October around the corner, we're already looking ahead: we'll be at GTC Berlin October 20-22. Here's what shipped and where we're headed next →

Claude Code can now work like a research scientist. K-Dense open-sourced 177 science skills for coding agents: - Drug discovery: query ChEMBL, screen molecules with RDKit and DiffDock - Single-cell RNA-seq analysis with Scanpy - 100+ scientific databases in one place - Biology, chemistry, medicine, physics, engineering, Earth science - Works with Claude Code, Codex and Cursor 52K stars. free. MIT license.

🧬 OTDC 2027 “Great medicines begin with precise molecules.” Explore advances in oligonucleotide therapeutics, RNA medicines & targeted delivery. 📅 May 11–12, 2027 | 📍 Boston, MA | Hybrid 🔗 #OTDC2027# #Oligonucleotides# #RNATherapeutics# #DrugDelivery#

ADARX PHARMACEUTICALS TARGETS $1.74B VALUATION IN U.S. IPO RNA drug developer ADARx Pharmaceuticals plans to sell 21.875M shares at $15-$17 each, raising up to $371.9M and valuing the company at as much as $1.74B. AbbVie will separately purchase about 5.01M shares in a concurrent private placement, giving it roughly a 4.9% stake after the IPO. ADARx is developing next-generation siRNA drugs, with five wholly owned programs spanning hereditary angioedema, complement diseases, stroke prevention, obesity and neurodegenerative diseases. Its most advanced drug, onvuzosiran, is currently in Phase 3 for hereditary angioedema, with topline data expected by the end of 2027. The FDA granted the program Fast Track status in August. At the $16 midpoint, ADARx expects roughly $397M in combined net proceeds from the IPO and AbbVie placement, with the largest allocations planned for: • $180M for agazisiran and its complement-disease programs • $80M for stroke candidate ADX-626 • $65M for Phase 3 onvuzosiran • $25M for obesity program ADX-077 • $20M for neurodegeneration program ADX-199 The company says the proceeds, together with existing cash and investments, should fund operations into 2030. ADARx plans to list on Nasdaq under $ADRX. Source: SEC filing, Reuters

How much will artificial intelligence transform the future of science? Nobel Prize laureate Craig Mello is joining us for a discussion in Seoul, South Korea about AI's future role in science. Together with other laureates and leading experts, they will explore what these changes mean for our ability to develop scientific solutions to the urgent challenges we face. Craig Mello received the Nobel Prize in Physiology or Medicine in 2006 for his work related to the discovery of RNA interference - gene silencing by double-stranded RNA. Discover more about the 2026 Nobel Prize Dialogue in Seoul:

An experimental RNA drug is being tested in pregnant women for the first time in an effort to treat preeclampsia without resorting to the only definitive option doctors currently have: delivering the baby.